Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 17/20 | 0.47 |
| ▸ | JAK1 | P23458 | 17/20 | 0.47 |
| ▸ | TYK2 | P29597 | 17/20 | 0.47 |
| ▸ | JAK3 | P52333 | 17/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436528 | 1.00 | KMT2A (0.50) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22121416 | 0.89 | KMT2A (0.57) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL19451470 | 0.84 | STING1 (0.48) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL28421225 | 0.84 | STING1 (0.48) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL29405998 | 0.84 | STING1 (0.48) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL20066406 | 0.84 | KMT2A (0.47) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22151665 | 0.83 | KDM4E (0.55) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL21643845 | 0.81 | STING1 (0.42) | KMT2A | |
| SCHEMBL21643841 | 0.81 | STING1 (0.42) | KMT2A | |
| SCHEMBL27204002 | 0.81 | STING1 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939343-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3440076-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939343-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | KMT2A 3969/4885JAK2 1168/4885JAK1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.